Data from the registry have led to increased use of clinical guidelines and changes in preoperative diagnostics for patients with low-risk prostate cancer with the introduction of the PSA test as a screening tool, which has reduced the need for extensive imaging. The gene discussed is KLK3; the disease is Familial prostate cancer.